Provenge, Dendreon's ($DNDN) pioneering cancer vaccine that disappointed investors last year with its sales, is under fire again. Reuters today spotlights former hedge-fund analyst Marie Huber and her journey to expose holes in the study that supported FDA approval of Provenge for treating prostate cancer in 2010. A scientist by training, Huber has been making a case that the placebo in the pivotal study might have caused harm to men who took the dummy treatment and made Provenge shine by comparison. There are many critics of Huber's analysis, including the doctors who led the Provenge trial. Article